Diabetes News

Endocrinology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Raskin P et al. – This study is to assess the efficacy and safety of a new repaglinide/metformin fixed–dose combination (FDC) tablet administered either twice a day (BID) or three times a day (TID) for the management of type 2 diabetes. The efficacy of twice–daily dosing of a repaglinide/metformin FDC tablet was non–inferior to that of three–times–daily dosing.

Related Articles

CYP2C8 Activity Recovers Within 96 Hours After Gemfibrozil Dosing: Estimation of CYP2C8 Half-life Using Repaglinide as an In Vivo Probe
Drug Metabolism and Disposition, 10/12/09    Relevance Score: 80%

Today in Pharmacology/kinetics...keeping you current

The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 12/04/09

Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis
Journal of Bone and Mineral Metabolism, 12/04/09

Myxedema Coma Associated with Combination Aripiprazole and Sertraline Therapy
Annals of Pharmacotherapy, 12/03/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address